IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#3408
Positioning
Market Dominance
Services
Computer Software
$13.7B
Jeffrey A. Tangney
Doximity, Inc. operates a cloud-based digital platform for medical professionals in the United States. It primarily serves pharmaceutical companies and health systems. The company was formerly known as 3MD Communications.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
X-AXIS: EV/EBITDA (LOWER = CHEAPER) | Y-AXIS: ROE (HIGHER = ELITE) | RED CIRCLE = DOCS ANALYSIS TARGET
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$YALA Yalla Group Ltd | 75 | 89 | 99 | 80 | - | - | 21.3% | 18.6% | 64.5% | 35.7% | 39.5% | 6.5% | 0.0% | 0.0x | $644M | VS | |
$GRVY GRAVITY Co., Ltd. | 75 | 82 | 96 | 71 | - | - | 15.4% | 12.6% | 38.7% | 17.1% | 17.0% | -39.7% | 0.0% | 0.0x | $439M | VS | |
$ISSC INNOVATIVE SOLUTIONS & SUPPORT INC | 73 | 81 | 88 | 94 | 25.0x | 14.1x | 28.1% | 16.8% | 48.1% | 23.8% | 18.5% | 78.6% | 0.0% | 37.0x | $220M | VS | |
$AER AerCap Holdings N.V. | 72 | 60 | 87 | 84 | - | - | 12.4% | 2.9% | 100.0% | 28.2% | 26.2% | 5.5% | 0.8% | 264.0x | $19.4B | VS | |
$HCSG HEALTHCARE SERVICES GROUP INC | 72 | 74 | 88 | 88 | 7.1x | 6.1x | 28.9% | 20.8% | 20.8% | 9.9% | 9.3% | 8.5% | 0.0% | 1.0x | $1.2B | VS | |
$LQDT LIQUIDITY SERVICES INC | 72 | 90 | 88 | 68 | 24.9x | 14.3x | 14.6% | 7.8% | 43.8% | 7.4% | 5.9% | 31.2% | 0.0% | 0.0x | $857M | VS | |
$TRTNpA Triton International Ltd | 71 | 70 | 89 | 70 | - | 1.7x | 18.0% | 4.6% | 97.3% | 52.2% | 32.7% | -3.4% | 0.0% | 271.0x | $8.0B | VS | |
$EDU New Oriental Education & Technology Group Inc. | 71 | 83 | 52 | 77 | - | - | 9.4% | 4.9% | 55.5% | 8.7% | 7.7% | 13.6% | 1.3% | 7.0x | $78.0B | VS | |
$NTES NetEase, Inc. | 71 | 88 | 93 | 68 | - | - | 22.1% | 15.6% | 62.5% | 28.1% | 28.7% | -1.0% | 2.8% | 9.0x | $56.6B | VS | |
$UTI UNIVERSAL TECHNICAL INSTITUTE INC | 70 | 86 | 86 | 72 | 43.2x | 16.0x | 21.4% | 8.0% | 100.0% | 10.0% | 7.5% | 14.1% | 0.0% | 27.0x | $1.8B | VS | |
$DOCS Doximity, Inc. | 41 | 65 | 49 | 14 | 21.4x | 19.4x | 22.6% | 19.1% | 89.8% | 38.2% | 34.7% | 46.1% | 0.0% | 18.0x | $13.7B | ||
| SECTOR BENCH | - | - | - | - | - | 23.7x | 11.7x | 5.3% | 1.9% | 59.6% | 3.5% | 2.3% | 7.8% | 0.0% | 0.3x | - | REF |
Doximity, Inc. (DOCS) receives a "Reduce" rating with a composite score of 41.1/100. It ranks #3408 out of 7,333 stocks in our coverage universe and carries a 2-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
YOY expansion rate
Core pricing power
Operating efficiency
Bottom-line conversion
Equity capital efficiency
Asset base utilization
Financial leverage load
Direct cash return
Jeffrey A. Tangney
Chief Executive Officer
Labor Force
890
65
32
38
Audit Verdict: Lower quality and stability scores may indicate governance concerns.
No recent insider transactions available for DOCS
Lagging peers — losers tend to keep underperforming
Fair valuation relative to peers
High profitability & efficiency — strong quality floor supports entry
Average volatility — neutral timing signal
Aggressive spending — empire-building risk, dilutive growth
Mid-range overall rating
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Services sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
Projection based on user-defined inputs. Re-calculated daily against current market data.
Reverse DCF Framework — Mauboussin Methodology
Institutional-grade Reverse DCF analysis. This model identifies the growth hurdles embedded in current market prices. When implied growth is significantly lower than historical or projected rates, a margin of safety may exist. Re-audited daily.
No analyst ratings for DOCS.
View All RatingsMaterial decline in asset turnover efficiency detected
| Factor | Global | Sector | Tilt |
|---|---|---|---|
| PROFITABILITY | 65 | 80 | -15DRAG |
| MOMENTUM | 14 | 9 | +5NEUTRAL |
| VALUATION | 49 | 50 | -1NEUTRAL |
| INVESTMENT | 32 | 41 | -9DRAG |
| STABILITY | 38 | 33 | +5NEUTRAL |
| SHORT INT | 48 | 46 | +2NEUTRAL |
Global = full universe. Sector = relative to industry peers. Positive tilt indicates idiosyncratic strength.
ROE proxy 22.6% (sector 5.3%)
GM 90% vs sector 60%, OM 38% vs sector 4%
Capital turnover N/A, R&D intensity 18.3%
Rev growth 46%, 5yr history
Interest coverage N/A
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
Doximity, Inc. receives a Reduce rating from our analysis, with a composite score of 41.1/100 and 2 out of 5 stars, ranking #3408 out of 7,333 stocks. DOCS's factor profile shows weakness across multiple dimensions, suggesting the stock may underperform going forward. Existing holders may want to consider trimming positions or tightening stop-losses.
DOCS earns a quality score of 65/100, indicating above-average business quality. The company reports a return on equity of 22.6% (sector avg: 5.3%), gross margins of 89.8% (sector avg: 59.6%), net margins of 34.7% (sector avg: 2.3%). Companies in this tier generally demonstrate consistent profitability and efficient capital deployment, though they may face some competitive pressure.
With a value score of 49/100, DOCS appears somewhat expensive relative to its fundamentals. Key valuation metrics include a P/E ratio of 21.35x, an EV/EBITDA of 19.40x, a P/B ratio of 4.82x. Investors paying a premium here are likely betting on above-average growth or margin expansion to justify current prices.
Doximity, Inc.'s investment score of 32/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of 46.1% vs. a sector average of 7.8% and a return on assets of 19.1% (sector: 1.9%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
Doximity, Inc. is experiencing notably weak momentum with a score of just 14/100. The stock has underperformed its peers and is trending below major moving averages. Revenue growth stands at 46.1% year-over-year, while a beta of 1.24 reflects its sensitivity to broader market moves. While deep momentum weakness can occasionally present value opportunities, it often reflects deteriorating fundamentals or structural headwinds that may persist.
DOCS's stability score of 38/100 signals elevated volatility and/or leverage concerns. Key stability metrics include a beta of 1.24 and a debt-to-equity ratio of 18.00x (sector avg: 0.3x). Investors should be prepared for wider-than-average price swings and consider position sizing accordingly to manage portfolio risk.
The short interest score of 48/100 for DOCS suggests somewhat elevated bearish positioning by institutional traders. Specific risk factors include above-average market sensitivity (beta: 1.24), elevated leverage (D/E: 18.00x). With a $13.7B market cap (large-cap), Doximity, Inc. may experience above-average volatility. Investors should consider whether the short thesis has merit or if it creates a potential short-squeeze opportunity.
Doximity, Inc. is a large-cap company in the Services sector, ranked #0 of 50 in its sector (100th percentile) and #3408 of 7,333 overall (54th percentile). Key comparisons include ROE of 22.6% exceeding the 5.3% sector median and operating margins of 38.2% above the 3.5% sector average. This top-quartile standing reflects exceptional competitive strength relative to Services peers.
While DOCS currently exhibits a REDUCE profile, superior opportunities exist within the SERVICES sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Services Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Momentum (14) would have the largest impact on the composite score.
EV/EBITDA 65% ABOVE SECTOR MEDIAN
ROE 325% ABOVE SECTOR MEDIAN (FAVORABLE)
Gross Margin 51% ABOVE SECTOR MEDIAN (FAVORABLE)
AUDIT DATA AS OF DEC 31, 2025 (Q3 FY2025)
We rate Doximity, Inc. (DOCS) as a Reduce with a composite score of 41.1/100 at a current price of $24.06. The quantitative profile shows weakness across multiple dimensions, suggesting limited upside potential and elevated risk of underperformance relative to peers over the next 12 months.
The rating is primarily driven by strength in quality (65th percentile) and value (49th percentile), which together account for the majority of the composite score. Offsetting weakness in momentum (14th percentile) and investment (32th percentile) tempers our overall conviction. We assign a Narrow Moat rating (65/100), Medium uncertainty, and Exemplary capital allocation.
Key items to watch: momentum to confirm whether the current price trend has legs; sustainability of the current growth rate. Any material change in these dynamics could warrant a reassessment of our rating. The moat trend is stable, which suggests the competitive landscape is stable for now.
Doximity, Inc. holds a top-quartile position (#0 of 50) within the Services sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 41.1/100 places it at rank #3408 in our full 7,333-stock universe. With a $13.7B market capitalization, Doximity, Inc. operates at meaningful scale within the Services sector, providing competitive advantages in distribution, procurement, and customer reach.
Revenue is growing at 46%, though momentum at the 14th percentile suggests the market has not yet fully recognized this trajectory. This potential disconnect between fundamental improvement and market recognition could represent an opportunity for patient investors if the growth trend persists.
The margin cascade tells an important story: gross margins of 90% (+30.3pp vs sector) narrow to operating margins of 38% (+34.7pp vs sector) and net margins of 34.7%, yielding a gross-to-net conversion rate of 39%. This efficient conversion suggests well-controlled operating costs and limited margin leakage between the gross and net levels.
At a current price of $24.06, Doximity, Inc. is trading near fair value based on current fundamentals. Our value factor score of 49/100 reflects a composite assessment across multiple valuation metrics including price-to-earnings, price-to-book, EV/EBITDA, and price-to-sales ratios relative to both sector peers and the broader market. Valuation metrics are mixed, with no strong signal of mispricing in either direction.
The stock currently trades at a P/E of 21.4x (roughly in line with the sector median of 23.7x), EV/EBITDA of 19.4x (at a premium), P/B of 4.8x, P/S of 7.4x. The below-sector P/E suggests possible undervaluation or the market pricing in near-term headwinds.
Gross margins of 90% signal strong pricing power and brand/IP advantages — businesses with margins above 40% have historically demonstrated more resilient earnings through economic cycles.
Returns on equity of 22.6% exceed the cost of equity for most companies, indicating genuine shareholder value creation and a reinvestment engine that compounds wealth over time.
Revenue growth of 46% confirms the business is expanding its addressable market — growth at this level typically supports multiple expansion and attracts institutional capital.
A conservative balance sheet (18% D/E) provides financial flexibility for acquisitions, buybacks, or weathering economic downturns without dilution.
Return on assets of 19.1% indicates efficient deployment of the full asset base, not just equity capital.
We assign a Medium uncertainty rating to Doximity, Inc.. The stock presents a balanced risk profile: below-average price stability (38th percentile). While not risk-free, the core business fundamentals are adequate to withstand moderate economic stress, and the range of potential outcomes around our fair value estimate is manageable.
Specific risk factors that inform our assessment include: below-average price stability (38th percentile). Each of these factors independently widens the distribution of potential outcomes, and in combination they create a risk profile that demands careful position sizing. The stability factor at the 38th percentile and quality factor at the 65th percentile provide a quantitative summary of the overall risk landscape.
Key risk mitigants include: healthy gross margins of 90% provide a buffer against cost pressures; conservative leverage (18% D/E) limits balance sheet risk. These factors partially offset the identified risks and provide downside protection in adverse scenarios. On balance, the risk-reward profile is favorable for long-term investors.
We rate Doximity, Inc.'s capital allocation as Exemplary. Management demonstrates a strong track record of balancing reinvestment with shareholder returns, evidenced by returns on equity of 22.6%, disciplined leverage (18% D/E), best-in-class net margins of 34.7%. Exemplary allocators typically generate returns on equity above 20% while maintaining debt-to-equity below 50% — Doximity, Inc. meets this high bar.
The balance sheet remains conservatively managed, providing financial flexibility for opportunistic investments while maintaining a margin of safety for shareholders. We note that the combination of 19.1% return on assets and controlled leverage suggests management is deploying capital at rates well above the cost of capital — the hallmark of exemplary stewardship.
In summary, Doximity, Inc. receives a Reduce rating with a composite score of 41.1/100 (rank #3408 of 7,333). Our quantitative framework assigns a Narrow Moat (65/100, trend: stable), Medium uncertainty, and Exemplary capital allocation. The average factor score across quality, value, momentum, stability, and investment is 39/100.
Our analysis does not support a constructive view on Doximity, Inc. at this time. The combination of the current quantitative profile, medium uncertainty, and exemplary capital allocation suggests unfavorable risk-reward at current levels. We recommend investors avoid new positions and existing holders consider reducing exposure.
Analysis derived from Blank Capital Research quantitative terminal. For informational purposes only. No trade solicitation. Past performance not indicative of future results. Consult a qualified advisor.
We assign Doximity, Inc. a Narrow Moat rating with a composite moat score of 65/100. The company possesses identifiable competitive advantages, though they are less entrenched than those of wide-moat peers. Our analysis indicates that Doximity, Inc. can sustain above-average returns on invested capital for at least 10 years, with the strongest contributor being margin superiority at 19.3/20.
The strongest moat sources are margin superiority (19.3/20) and growth durability (17.5/20). GM 90% vs sector 60%, OM 38% vs sector 4%. Rev growth 46%, 5yr history. These pillars form the core of Doximity, Inc.'s competitive identity and are the primary drivers of excess returns in our framework.
Areas of relative weakness include reinvestment efficiency (6.4/20) and financial resilience (8.9/20). Capital turnover N/A, R&D intensity 18.3%. Improvement in these areas could meaningfully widen the moat over time, while deterioration would be an early warning of competitive erosion.
Our moat trend assessment is Stable. Multi-year ROIC and operating margin trajectories show neither meaningful improvement nor deterioration, suggesting the competitive position is steady. We expect Doximity, Inc.'s moat profile to remain largely unchanged absent a material shift in return on capital or industry dynamics.
Key profit drivers include gross margins of 90% providing a solid profitability foundation, operating margins of 38% reflecting effective cost management, robust top-line growth of 46% expanding the revenue base. The margin cascade from 90% gross to 38% operating to 34.7% net reveals the company's cost structure and reinvestment intensity. Our analysis indicates that the profit engine is high-quality and likely sustainable, with the quality factor at the 65th percentile.
The margin profile shows gross margins of 90%, operating margins of 38%, net margins of 34.7%. Return metrics include ROE of 22.6% and ROA of 19.1%. Relative to the Services sector, gross margins are 30.3 percentage points above the sector median of 60%, and ROE of 22.6% compares to a sector median of 5.3%.
The balance sheet reflects a conservatively managed balance sheet with D/E of 18%, revenue growth of 46%. The sector median D/E is 0%, putting Doximity, Inc. at higher leverage than the typical peer. The combination of low leverage and healthy profitability provides significant financial resilience and strategic optionality.
The Reduce rating (composite 41.1/100) reflects multi-factor weakness, and historically, stocks in this scoring range have underperformed the market by a meaningful margin.
Weak momentum (14th percentile) suggests institutional selling pressure and unfavorable technical dynamics that may persist.

Doximity (DOCS), a social network and software platform for doctors, has fallen 66% over the past year amid software stock selloffs driven by AI disruption fears. Despite the stock decline, the underlying business remains strong with 89.75% gross margins, 38.5% EBIT margins, and a dominant position serving 85% of U.S. physicians. Trading at a P/E of 21, the stock presents a buying opportunity for investors as the company expands into new software tools like DoxGPT.

William Blair Investment Management sold 372,184 shares of Doximity (worth ~$21 million) in Q4 2025, reducing its position by 15%. Despite the sale, the author remains bullish on Doximity, citing its reasonable 17x free cash flow valuation, strong physician adoption (85% of U.S. doctors), and upcoming AI monetization opportunities in 2026. The stock has declined 66% year-over-year, partly due to temporary pharma spending delays that are now subsiding.

Two healthcare stocks, Hims & Hers Health and Doximity, have seen significant stock price growth over the past year, with potential for continued expansion in digital health and professional networking platforms.

Doximity reported Q1 FY2026 results with revenue of $145.9 million, missing analyst expectations but beating earnings per share estimates. The company raised full-year guidance and showed strong performance in AI tool adoption and workflow solutions.
Above 50MA
37.18%
Net New Highs
+51081